To Efficacy


We are dedicated to the discovery of novel therapeutics by creating and testing patient derived cancer xenograft models

NexusPharma offers a unique collection of over 150 proprietary Patient-Derived Xenograft (PDX) and preclinical cancer models of various tumor types for in vivo efficacy studies to evaluate novel antitumor agents. We also have a matching set of 61 PDX-derived cell lines for ex vivo drug screening.

Our database provides access to information about our extensively characterized PDX models including mutational analysis (eg., KRAS, TP53, BRCA1, 2), gene expression profiles (eg. HER2 positive, c-Myc overexpression etc.) patient treatment and drug response data, growth curves, histology and much more.

View an overview of our services